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ABSTRACT
Introduction: Rotational total skin electron
irradiation (RTSEI) is an effective therapy for
cutaneous T cell lymphoma (CTCL). CD30
expression has been identified as a prognostic
factor in CTCL. Therefore, we investigated
CD30 status, treatment response, and survival
in our cohort of patients with CTCL treated
with RTSEI.
Methods: Patients with CTCL treated with
RTSEI (C30 Gy) between 2000 and 2013 at our
institution were identified, and clinical and
pathologic data were retrospectively reviewed.
Primary outcomes were complete clinical
response (CCR;[90% reduction of skin disease
burden), relapse-free survival (RFS), and overall
survival (OS).
Results: Sixty-eight patients with CTCL treated
with RTSEI were identified. Median age at
diagnosis was 51 years with median follow-up
of 61 months. Median OS was 76 months and
median RFS was 11 months. Thirteen patients
(19%) had CD30? lymphocytes on initial
pathology. In the CD30? cohort, there were
no T2, eight T3, and five T4 cases. In
comparison, in the CD30- cohort, there were
18 T2, 29 T3, and 8 T4 cases (P = 0.01).
Six weeks post-RTSEI, CCR was 85% in CD30?
and 81% in CD30- cases (P = 1). Six months
post-RTSEI, CCR was 23% in CD30? and 50% in
CD30- cases (P = 0.083).
Conclusion: RTSEI resulted in excellent CCR at
6 weeks in our cohort of patients with CTCL,
with a median RFS of 11 months. We found
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CD30? patients presented with significantly
higher T stage at time of RTSEI and trended
towards decreased CCR at 6 months post-RTSEI
compared with the CD30- group.
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INTRODUCTION
Cutaneous T cell lymphoma (CTCL) is a rare
group of lymphoproliferative disorders
characterized by localization of T lymphocytes
to the skin with an overall incidence of
10.2 cases per million person-years [1]. It is
becoming increasingly recognized that CTCL is
heterogeneous, with multiple variants that have
unique clinical presentations, histologic
features, and therapeutic considerations [2].
The most common subtype of CTCL is
mycosis fungoides (MF), which typically
presents with pruritic patches and plaques in
areas of skin not commonly exposed to sun, and
may evolve to cutaneous tumors or
erythroderma [3]. Demographic features
including African-American race, male gender,
and age have been found to be risk factors for
CTCL, while extent of skin involvement, overall
disease stage, and age are prognostic indicators
[2, 3]. The prognostic significance of
lymphocytic CD30 positivity in CTCL
prognosis remains controversial: some have
reported it as a favorable prognostic factor, [4]
while others have shown it to be associated with
advanced disease and independently associated
with poorer survival [5].
Total skin electron irradiation (TSEI) has
been shown to be an effective palliative
treatment for CTCL, even following failure
with previous treatment modalities. This has
been demonstrated in multiple retrospective
reviews showing that conventional dose
(C30 Gy) TSEI achieves high clinical response
rates [3, 6–11] typically using
large-field/modified Stanford technique
(discontinuous irradiation). However, more
recent clinical series using dual-field rotational
TSEI (RTSEI) technique, where a patient is
rotated at a constant speed about the vertical
axis while being irradiated with continuous
dual-field irradiation (providing a theoretical
advantage in dose homogeneity compared to its
large-field/modified Stanford counterpart),
showed promising results [12, 13]. Given that
there have been no previous studies that have
examined the response of CD30? CTCL to
RTSEI, we investigated the effect of CD30
status on treatment response and survival in




After institutional review board (IRB) approval
was obtained from Emory University for this
study, we retrospectively reviewed medical
records of patients treated with RTSEI
identified from billing records. Patients were
treated between 2000 and 2013 at Emory
University, Atlanta, GA, USA. Patient
electronic medical records and a previous
IRB-approved dermatology database were used
to ascertain information regarding
demographics, diagnosis, histology, staging,
treatment regimens, RTSEI treatment, clinical
response, recurrence, and overall survival (OS).
Eligibility criteria for the study included:
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histologically confirmed CTCL and a completed
first course of conventional dose (C30 Gy)
RTSEI. All patients were staged based on 2007
ISCL EORTC T and group stage definitions [14].
We identified patients as CD30? based on
initial pathology reports of skin biopsy. All
CD30? patients slides were reviewed by a
board-certified hematopathologist (K.B.).
Pathologists typically perform CD30
immunohistochemistry when there is concern
for transformation with increased numbers of
large lymphoid cells. CD30-not-tested cases
lacked histological evidence of transformation
and thus were grouped for statistical purposes
with those that are known to be CD30 negative
per pathology report.
Treatment Technique
RTSEI was administered using a 21EX Varian
linear accelerator (LINAC; Varian, Palo Alto, CA,
USA) equipped with 6 MeV high-dose total skin
electron (HDTSe) mode at a dose rate of
888 MU/min. RTSEI used dual angles field at
gantry angles of 241 and 299 to cover the
upper and the lower halves of the patient body.
In the 6 MeV HDTSe mode, our LINAC
calibration was 2.99 cGy/MU at a maximum
source to skin distance (SSD) of 100 cm. The
patient is placed on a rotating platform at an
extended SSD (315 cm) from the gantry. Both
arms are raised overhead and are positioned on
the rotator vertical bars. The platform rotates at
a constant speed of four revolutions per minute
to ensure adequate surface dose buildup.
All patients were treated using a standard
method: 36 Gy delivered at 1.5 Gy per fraction,
administered three times weekly, typically on a
monday–wednesday–friday schedule (4.5 Gy/
week). Eye shields were used upon treatment
initiation. Finger/toe nail shields were added
after 12 Gy. A one-week mid-treatment break
was allowed after delivery of 18 Gy. Optically
stimulated luminescent dosimeter (OSLD)
measurements at typically under-dosed areas
including but not limited to scalp, palms, inner
thighs, and bottom of feet were taken prior to
the mid-treatment break. Approximately 84% of
patients received additional boost to these
under-dosed regions based on clinical
assessment of disease response at the end of
RTSEI. In total, the total RTSEI regimen required
9 weeks followed by a 2–3-week boost portion.
Covariates
The overall study cohort was compared across
the following covariates: sex, age at diagnosis,
age at RTSEI, histology, T stage at start of RTSEI,
pre-RTSEI CTCL treatments (therapies received
prior to primary RTSEI course including topical,
systemic antineoplastic, systemic dermatologic,
and phototherapies), maintenance therapy
(systemic or topical therapy started within
3–6 months after RTSEI), time from diagnosis
to RTSEI, and recurrence.
Outcome Measures
Primary outcome measures were complete
clinical response (CCR) rate, relapse-free
survival (RFS), and OS. CCR rate was defined
as the proportion of follow-up patients with at
least 90% reduction in cutaneous tumor
burden. Patients considered non-complete
responders (non-CR) included those with
partial response ([50% reduction but less than
90%), stable disease, recurrence, progression, or
death at each of three time points: (1) end of
RTSEI treatment, (2) 6 weeks post-RTSEI, and (3)
6 months post-RTSEI. Patients with no previous
record of recurrence, those who did not
follow-up or had no recorded clinical response
at one of the time points were not included in
Dermatol Ther (Heidelb) (2016) 6:251–263 253
the CCR proportion. Response rates were
compared across CD30 status and by T stage
using Chi-square or Fisher’s exact test, as
appropriate.
RFS was calculated as the number of days
between start of RTSEI and the date of
recurrence. In the case of patients who did not
have recurrence, RFS was censored at the date of
last follow-up or date of death. OS was the
number of days between diagnosis and the date
of death or last known follow-up. RFS and OS
distributions were estimated using the
Kaplan–Meier method. Both RFS and OS were
compared across race, T stage, and previously
mentioned covariates, using log-rank tests and
Cox proportional hazards models. Multivariate
Cox models were fit, adjusting for T stage
pre-TSEI, and the proportional hazards
assumption was checked for all models. The
cutoff for statistical significance for all analyses
was set at the two-sided alpha error of 0.05. All




Medical records of 110 patients treated with
RTSEI identified from billing records were
retrospectively reviewed. After excluding 42
patients who either had a primary diagnosis of
leukemia cutis or did not complete
conventional dose RTSEI, 68 eligible patients
remained. Individual case summaries of all
CD30? patients are shown in Table 1. Patient
characteristics of the study cohort, stratified by
CD30 status, are summarized in Table 2.
Sixty-eight patients were treated with
conventional dose RTSEI (range 30–36 Gy).
Median age at time of diagnosis was 51 years.
Median follow-up was 61 months. Median time
from diagnosis until RTSEI was 35 months. Six
patients (46%) received maintenance therapy
following RTSEI. Seven patients (42%) recurred
following RTSEI. Median follow-up time for
these patients was 80.2 months.
Pathology confirmed 13 (19%) CTCL
patients as CD30?. CD30% expression ranged
from 5% to 30% in tumor cells. An example
photomicrograph of a CD30? transformed
CTCL case is shown in Fig. 1. For the CD30?
patients, 7 (54%) were female and 6 were male
(46%), and 7 were AA (54%) and 6 were white
(46%). CD30? patients had a significantly more
advanced T stage disease prior to RTSEI (62% T3,
39% T4) compared to CD30- patients (33% T2,
53% T3, 15% T4; Table 2). There were no
significant differences between CD30
subgroups in regard to sex, race, age at
diagnosis, time from diagnosis to RTSEI,
treatments prior to RTSEI, maintenance
therapy, follow-up time, or proportion that
recurred after RTSEI.
Clinical Response Rates
Table 3 summarizes CCR rates by CD30 status.
CD30? patients had overall CCR rates of 85% at
end of RTSEI, 85% at 6 weeks follow-up, 23% at
6 months follow-up. CD30- patients had
overall CCR rates of 95% at the end of RTSEI,
79% at 6 weeks follow-up, and 50% at 6 months
follow-up. Chi-square and Fisher’s exact tests
revealed no significant differences in CCR rate
between CD30 status subgroups following end
of RTSEI (P = 0.24) or six weeks (P = 0.44), but
did trend toward significance at 6 months
post-TSEI (P = 0.083). This trend was driven by
a significantly poorer response at 6 months for
CD30? T3 disease compared to CD30- T3
patients (P = 0.04). Further comparisons
between CD30 status groups across respective
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Table 2 Patient characteristics
Covariate CD30 status P value
CD302 (n 5 54) CD301 (n5 14)
Sex, n (%)
Female 26 (47.3) 7 (53.9) 0.67
Male 29 (52.7) 6 (46.2)
Race, n (%)
White 27 (50.9) 6 (46.2) 0.76
African-American 26 (49.1) 7 (53.9)
Age, mean 52.4 56.2
Time (months) from diagnosis to RTSEI
Median 16.8 35.4 0.30
Mean 27.2 35.8
Pre-RTSEI tumor (T) stage, n (%)
T2 18 (32.8) 0 (0.0) 0.01
T3 29 (52.7) 8 (61.5)
T4 8 (14.6) 5 (38.5)
Pre-RTSEI CTCL treatment
Previous use of topical agents, n (%)
No 25 (45.5) 5 (38.5) 0.65
Yes 30 (54.6) 8 (61.5)
Previous use of systemic antineoplastic agents, n (%)
No 27 (49.1) 6 (46.2) 0.85
Yes 28 (50.9) 7 (53.9)
Previous use of systemic dermatologic agents, n (%)
No 43 (78.2) 12 (92.3) 0.44
Yes 12 (21.8) 1 (7.7)
Previous use of phototherapy, n (%)
No 29 (52.7) 6 (46.2) 0.67
Yes 26 (47.3) 7 (53.8)
Maintenance therapy post-RTSEI, n (%)
No 35 (63.6) 7 (53.9) 0.54
Yes 20 (36.4) 6 (57.1)
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Fig. 1 Transformed cutaneous T cell lymphoma (Case #9
from Table 1). a Large transformed lymphoma cells with
focal epidermotropism (H&E stain, original magniﬁcation
9200). b Approximately 30% of lymphoma cells are
positive for CD30 (original magniﬁcation 9200)
Table 2 continued
Covariate CD30 status P value
CD302 (n 5 54) CD301 (n5 14)
Recurrence following RTSEI, n (%)
No 18 (32.7) 6 (46.2) 0.42
Yes 37 (67.3) 7 (53.9)
CTCL cutaneous T cell lymphoma, RTSEI rotational total skin electron irradiation
Bold P values are statistically signiﬁcant (P\ 0.05)





End of RTSEI Six weeks post-RTSEI Six months post-RTSEI














All T stages 11 (85) 52 (95) 0.24 11 (85) 42 (79) 1 3 (23) 24 (50) 0.083
T2 – 18 (100) – – 15 (88) – – 5 (42) –
T3 7 (88) 27 (93) 0.53 7 (88) 22 (79) 1 1 (13) 16 (57) 0.044
T4 4 (80) 7 (88) 1 4 (80) 5 (62.5) 1 2 (40) 3 (38) 1
Bold P values are statistically signiﬁcant (P\ 0.05)
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T stages at all other follow-up time points
showed no significance difference in CCR rates.
Relapse-Free Survival
As seen in Table 4, CD30? patients had a
median RFS of 12.1 months (8.3 and 13.2 for
T3 and T4 disease, respectively, not significantly
different). CD30- patients had a median RFS of
9.9 months (14.3, 11.3, and 6.0 months for T2,
T3, and T4 disease, respectively, with no
significant difference between stages T3 and
T4). Kaplan–Meier RFS curves comparing CD30
groups and CD30? patients by T stage are
shown in Fig. 2.
On multivariate analysis, controlling for
T stage, CD30 status was not associated with
RFS (P = 0.75). Maintenance therapy following
RTSEI was associated with significantly
improved RFS in CD30- group [hazard ratio
(HR) = 2.79; 95% confidence interval (CI)
1.17–6.66; P = 0.021]. This association was not
observed in the CD30? group (P = 0.383). All
other covariates such as race, sex, T stage,
histology, age at diagnosis, time from
diagnosis to start of TSEI, and pre-RSTEI
treatment did not have a clinically significant
association with RFS on univariate or
multivariate analyses in either CD30? or
CD30- groups.
Overall Survival
As seen in Table 4, CD30? patients had a
median OS of 103.3 months overall with no
significant difference in OS between stages T3
and T4 (P = 0.65). CD30- patients had a
median OS of 74.5 months with a trend
towards poorer survival for T4 compared to T3
patients (103.3 months for T3, 30.5 months for
T4, P = 0.09). There was no significant
difference in OS across CD30 status (P = 0.57),
T3 (P = 0.95), or T4 (P = 0.10) subgroups.
Kaplan–Meier OS curves for comparing CD30
groups and CD30? patients by T stage are
shown in Fig. 2.
On univariate analysis, CD30 status was not
associated with OS (P = 0.57). In the CD30?
group, non-MF histology (compared to MF
histology) was associated with poorer OS in
univariate analysis (HR = 10.65; P = 0.025).
However, after controlling for T stage
pre-RTSEI, this observed effect only trended
towards significance (P = 0.080). In the CD30-
group, lower T stage (HR = 0.26; P = 0.049) in
univariate analysis was associated with
Table 4 RFS and OS, stratiﬁed by T stage pre-RTSEI and CD30 status
T stage pre-RTSEI Median RFS (months) Median OS (months)
CD302 CD301 P value CD302 CD301 P value
All T stages 9.9 12.1 0.75 74.5 103.3 0.57
T2 14.3 – – – – –
T3 11.3 8.3 0.64 103.3 90.7 0.95
T4 6.0 13.2 0.51 30.5 – 0.10
OS overall survival, RFS relapse-free survival, RTSEI rotational total skin electron irradiation
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improved OS. In multivariate analysis,
increased time from diagnosis to RTSEI
(HR = 0.98, P = 0.017) and younger age at
RTSEI (HR = 1.06; P = 0.003) were associated
with a significantly improved OS. Maintenance
therapy failed to show any significant
improvement in OS in both CD30?
(P = 0.998) and CD30- (P = 0.242) in
multivariate analysis controlling for T stage
pre-RTSEI.
Fig. 2 Survival outcomes. a RFS comparing CD30? vs.
CD30- patients. b OS comparing CD30? vs. CD30-
patients. c RFS for CD30? patients comparing stage T3
and T4 pre-RTSEI. d OS for CD30? patients comparing
stage T3 and T4 pre-RTSEI. OS overall survival, RFS
relapse-free survival, RTSEI rotational total skin electron
irradiation
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DISCUSSION
At present there in no long-term curative
treatment for CTCL. Management is difficult
as there are no standardized treatment
regimens, there is prognostic heterogeneity
even within group stages, and high-quality
trials are lacking due to disease rarity. There is
an urgent need to identify patients at high or
low risk for disease progression or mortality to
aid in clinical decisions about treatment
including escalation/de-escalation of radiation
dose or initiation/holding of systemic agents.
Since treatment for CTCL, especially
advanced-stage disease, is palliative, improved
prognostication would help avoid treatment
toxicity in cases at low risk for progression.
Recently, the prognostic Cutaneous Lymphoma
International Prognostic index (CLIPi) was
developed for early- and late-stage MF using a
cohort of 1502 UK patients and validated in a
set of 1221 patients treated at MD Anderson
Cancer Center (MDACC; Houston, TX, USA);
however, this has yet to be validated in a
prospective manner [15–17]. The Cutaneous
Lymphoma International Consortium (CLIC)
developed a prognostic score for advanced MF
stage IIB to IV and Sezary syndrome (SS) with
1394 patients from 29 centers worldwide
including the following factors: stage IV
disease, age greater than 60 years, large cell
transformation, and elevated serum lactate
dehydrogenase [18].
CD30 is a member of the tumor necrosis
receptor family, and is found on activated T and
B cells. A recent study of 47 non-transformed
MF cases from the University of Pittsburgh
(Pittsburgh, PA, USA) reported that patients
were found to have worse survival, higher
stage at diagnosis, and higher maximum stage
if dermal cells are CD30? ([4.7%) [5]. A study
of 51 patients with large cell transformation of
MF at Memorial Sloan Kettering Cancer Center
(New York, NY, USA) reported that
predominance of CD30 in the epidermis rather
than dermis was associated with poorer survival
[19]. However, a retrospective analysis of 100
patients with transformed MF from the
Netherlands showed that CD30 negativity was
associated with multivariate analysis with
reduced disease-specific survival (DSS) and OS
[4]. In a long-term outcomes study, CD30 was
found to have no significant effect on OS, DSS,
and progression-free survival (PFS) in 1263 MF
SS patients at MDACC [17]. The CLIC reported
that when CD30 is scored positive above 10% of
tumoral cells, it is not statistically significant for
OS but is associated with worse OS in the subset
of patients with T3 disease [18]. Finally, CD30 is
also targetable with brentuximab vedotin, a
monoclonal chimeric antibody conjugated to
antitubulin agent monomethyl auristatin E. A
recent phase 2 study found that brentuximab
vedotin has significant objective global
response 70% (21/30) in treatment patients
with refractory or advanced MF/SS who have a
range of CD30 expression levels [20]. Similarly,
another phase 2 trial found overall response of
73% (35/48) in patients with CD30?
lymphoproliferative disorders treated with
brentuximab vedotin [21].
Based on the varying reports of the
prognostic significance of CD30, we sought to
assess the response and survival of our cohort of
patients treated with RTSEI. We found 13 of 68
patients were CD30? (range 5% to 30%); they
presented with significantly higher T stage at
time of RTSEI and trended towards decreased
CCR at 6 months post-RTSEI compared with the
CD30- group. One patient in our cohort had
1% CD30? lymphocytes on pathology and was
classified as negative for CD30; however, when
this patient was added to the CD30? cohort
(data not reported in results) the CCR was
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significantly reduced at 6 months (P = 0.05).
Regardless, the difference in 6 month CCR was
primarily driven by those with T3 stage disease.
Overall, CD30? patients had excellent CCR
rates of 85% at end of RTSEI but most had
progressive disease at 6 months. Maintenance
therapy including topical, systemic
antineoplastic, systemic dermatologic, and
phototherapies failed to show any significant
improvement in RFS in the CD30? group.
Additionally, maintenance therapy failed to
show any significant improvement in OS in
both CD30? and CD30- groups. Although
direct comparison is not possible without
further study, our rates of clinical response are
comparable to those recently reported for
brentuximab vedotin.
Additionally, CD30? patients may benefit
from the addition of novel targeted agents such
as Brentuximab vedotin to radiation, perhaps
concurrently or sequentially. Recently, the
concept of combined radiation and
immunotherapy to enhance clinical outcomes
has advanced. To date there is no trial of the
safety of brentuximab vedotin with radiation.
We feel prospective trial development of
combined brentuximab vedotin and radiation
for CTCL should proceed based on the results of
recent phase 2 trials.
Our analysis is limited by small sample size;
however, this is the largest report of CD30?
patients, and their response to radiotherapy.
More specifically, the small sample size
precluded us from examining in more detail
the role of maintenance systemic and
dermatologic agents. In addition, if a patient
did not follow up or did not have a recorded
clinical response at the specified time points
without record of recurrence by other providers,
they were excluded from CCR analysis which
further decreased patient numbers in the
present analysis. Additionally, as this was a
retrospective review, many patients had
incomplete clinicopathological information,
information from outside hospitals, or were
lost to follow-up. Incomplete data regarding
CD30 status increases confounding as patients
deemed by clinicians to have aggressive disease
or transformation often have more thorough
workup. Strengths of our study included
documentation of clinical response across
multiple post-treatment time points, single
institution experience with standardized RTSEI
delivery and dosing, and all CD30? cases were
reviewed by a hematopathologist to confirm
CD30 status.
CONCLUSIONS
In this retrospective study, RTSEI for CTCL
resulted in excellent CCR at 6 weeks, with a
median RFS of 11 months. This is consistent
with and improves upon treatment results
reported previously. CD30? patients receiving
RTSEI were found to have higher T stage and
trended towards decreased CCR at 6 months
post-RTSEI compared with the CD30- patients.
Maintenance therapy including topical,
systemic antineoplastic, systemic
dermatologic, and phototherapies failed to
show any significant improvement in RFS in
the CD30? group. Future work should examine
quality of life metrics, the role of maintenance
systemic or targeted treatments, and
combination RTSEI and brentuximab vedotin
in CD30? patients with CTCL.
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